Researchers at the Hebrew University of Jerusalem have demonstrated that CBD and CBG can significantly reduce hepatic steatosis and improve insulin sensitivity. The study, published in the British Journal of Pharmacology, suggests that these cannabinoids "reboot" the liver's cellular cleaning system, offering a potential new therapeutic pathway for metabolic dysfunction-associated steatotic liver disease (MASLD).
Comparative Impact of CBD and CBG on Liver Metabolism
The following table summarizes the physiological improvements observed in the MASLD mouse models following four weeks of cannabinoid treatment.
| Metabolic Marker | Effect of CBD & CBG Treatment |
|---|---|
| Hepatic Steatosis (Liver Fat) | Significant reduction in triglycerides and harmful lipid buildup. |
| Blood Sugar Control | Enhanced glucose regulation and restored insulin sensitivity. |
| Cellular Cleansing (Autophagy) | Reactivation of cathepsins to eliminate cellular toxins. |
| Energy Storage | Restored ability to store energy and eliminate metabolic waste. |
Metabolic Remodeling: How Cannabinoids Restore Liver Function
The research, conducted at the Hebrew University of Jerusalem’s Faculty of Medicine, focused on mice that had developed MASLD after 14 weeks on a high-fat diet. By administering CBD (cannabidiol) and CBG (cannabigerol) via peritoneal injections, researchers observed a profound "metabolic remodeling." This process altered how the liver stores and utilizes energy, making more fuel available for the body while clearing harmful fat deposits.
A critical finding of the study was the reactivation of cathepsins. These enzymes act as a cellular cleaning system, breaking down proteins and toxins that contribute to liver inflammation. By rebooting this system, CBD and CBG helped the liver cells manage energy more efficiently and clear the "fatty buildup" (steatosis) often associated with diabetes, high blood pressure, and obesity.
The Path to Human Trials
While the results in the British Journal of Pharmacology are highly promising, the study authors emphasize that these findings are currently limited to preclinical models. The next phase of research must address the pharmacokinetics and delivery routes of these phytocannabinoids in humans. Because MASLD is a leading cause of chronic liver disease worldwide, the potential for non-psychoactive cannabinoids to serve as a low-toxicity treatment option represents a significant shift in hepatology.
Expert Verdict: A New Frontier in Hepatology
From an analytical standpoint, this study is the first to prove that cannabinoids can fundamentally alter the liver's energy-storage mechanisms. While CBD has long been studied for its anti-inflammatory properties, the inclusion of CBG as a metabolic regulator opens a new therapeutic window. For patients with MASLD, the ability to restore insulin sensitivity and "reboot" cellular cleansing without the psychoactive effects of THC is a major clinical breakthrough. However, until human trials confirm safety and efficacy, these compounds remain a "promising future intervention" rather than a current clinical standard.
